Thermo Fisher Scientific Inc. $TMO Holdings Trimmed by ICICI Prudential Asset Management Co Ltd

ICICI Prudential Asset Management Co Ltd lowered its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 38.9% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 10,821 shares of the medical research company’s stock after selling 6,899 shares during the quarter. ICICI Prudential Asset Management Co Ltd’s holdings in Thermo Fisher Scientific were worth $6,270,000 at the end of the most recent quarter.

Several other large investors have also bought and sold shares of TMO. High Note Wealth LLC boosted its stake in Thermo Fisher Scientific by 170.6% during the fourth quarter. High Note Wealth LLC now owns 46 shares of the medical research company’s stock valued at $27,000 after buying an additional 29 shares in the last quarter. JPL Wealth Management LLC bought a new position in Thermo Fisher Scientific during the third quarter valued at about $28,000. Beacon Financial Strategies CORP bought a new position in Thermo Fisher Scientific during the fourth quarter valued at about $29,000. Olistico Wealth LLC bought a new position in Thermo Fisher Scientific during the fourth quarter valued at about $29,000. Finally, Core Wealth Advisors LLC bought a new position in Thermo Fisher Scientific during the fourth quarter valued at about $30,000. Institutional investors own 89.23% of the company’s stock.

Insider Buying and Selling at Thermo Fisher Scientific

In other news, COO Gianluca Pettiti sold 400 shares of the firm’s stock in a transaction dated Monday, April 27th. The stock was sold at an average price of $462.66, for a total transaction of $185,064.00. Following the completion of the sale, the chief operating officer directly owned 25,051 shares of the company’s stock, valued at $11,590,095.66. This trade represents a 1.57% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.33% of the stock is owned by company insiders.

Thermo Fisher Scientific Trading Down 1.4%

Shares of NYSE TMO opened at $475.12 on Friday. Thermo Fisher Scientific Inc. has a one year low of $385.46 and a one year high of $643.99. The company has a current ratio of 1.53, a quick ratio of 1.15 and a debt-to-equity ratio of 0.77. The firm has a market capitalization of $176.56 billion, a PE ratio of 26.12, a PEG ratio of 2.13 and a beta of 0.88. The business has a 50-day moving average price of $479.68 and a two-hundred day moving average price of $528.09.

Thermo Fisher Scientific (NYSE:TMO) last announced its quarterly earnings data on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, topping the consensus estimate of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The business had revenue of $11.01 billion during the quarter, compared to analyst estimates of $10.86 billion. During the same period last year, the company earned $5.15 earnings per share. Thermo Fisher Scientific’s quarterly revenue was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. As a group, analysts predict that Thermo Fisher Scientific Inc. will post 24.86 earnings per share for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, July 15th. Stockholders of record on Monday, June 15th will be paid a dividend of $0.47 per share. The ex-dividend date of this dividend is Monday, June 15th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. Thermo Fisher Scientific’s dividend payout ratio (DPR) is 10.34%.

Wall Street Analyst Weigh In

TMO has been the subject of a number of recent analyst reports. DZ Bank started coverage on Thermo Fisher Scientific in a research report on Friday, March 27th. They issued a “buy” rating and a $610.00 price target for the company. Wells Fargo & Company cut their price objective on Thermo Fisher Scientific from $675.00 to $615.00 and set an “overweight” rating on the stock in a report on Friday, May 8th. HSBC downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating and cut their price objective for the stock from $670.00 to $540.00 in a report on Wednesday, June 3rd. Jefferies Financial Group upgraded Thermo Fisher Scientific to a “strong-buy” rating in a report on Friday, April 24th. Finally, Royal Bank Of Canada set a $490.00 price objective on Thermo Fisher Scientific and gave the stock a “sector perform” rating in a report on Thursday, May 14th. Two analysts have rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and five have given a Hold rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $608.95.

Thermo Fisher Scientific Profile

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.